Abstract:Backgrounds: Percutaneous transseptal transcatheter mitral valve-in-valve implantation (TMViV) has become an alternative minimally invasive treatment choice for patients with degenerated mitral bioprosthesis and high surgical risk. However, transseptal approach is more technically challenging than transapical approach in TMViV procedures. Objective: The objective of this study was to introduce the experience of applying long pre-curved sheaths in transseptal TMViV procedures and to evaluate the effect of long pre-curved sheath techniques in TMViV procedures. Methods: Between January 2020 and December 2021, 27 patients with degenerated bioprosthetic mitral valve underwent TMViV procedures using a balloon-expandable valve via the transseptal approach. The regular 14/16F expand-able sheath were used for low-profile delivery in first 10 cases, and 22F long pre-curved sheath were used in the next 17 cases during procedures. We retrospectively reviewed the catheter techniques, perioperative characteristics, and prognosis. The median follow-up time was 12 (1-21) months. To further scrutinize our data, we divided the group into the early 10 patients using 14/16F expandable sheath and the subsequent 17 patients with long pre-curved sheath in order to assess the impact of different sheaths and procedural details on outcomes. Results: Procedural success was obtained in all patients with no in-hospital mortality. Seventeen patients received 26 mm prostheses; the remaining ten patients received 29 mm prostheses. Post balloon dilatation was performed in one case. Total procedure time was (96.1 +/- 28.2) min, the fluoroscopic time was (27.4 +/- 6.5) min, and total contrast volume was (50.7 +/- 10.1) mL. One patient received blood transfusion because of hemorrhage at the femoral puncture site. One patient received a permanent pacemaker implan-tation due to high-degree atrioventricular block at postoperative day 3. There were no other major post-procedure complications and the median length of hospital stay was 4 days. Twenty-five (92.6%) patients improved by >= 1 New York Heart Association (NYHA) functional class at 30 days. In subsequent sub analysis, there were shorter procedural time [(85.2 +/- 24.3) vs. (115.2 +/- 25.6) min, p = 0.0048] and shorter fluoroscopic time [(24.3 +/- 5.2) vs. (31.3 +/- 5.1) min, p = 0.0073] in cases with the long pre-curved sheath than ones with regular expandable sheath. The iatrogenic atrial septal defect (ASD) closure was performed because of the transeptal large right to left shunt in 2 cases with regular expandable sheath, but no patient needed intraoperative ASD closure in cases with the long pre-curved sheath. Conclusions: Transseptal TMViV using long pre-curved sheath could simplify transseptal approach with reliable outcomes for patients of degenerated mitral bioprosthesis.

Transcatheter mitral valve implantation in severely calcified rheumatic mitral stenosis without annular calcification

Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease: A systematic review

Transcatheter mitral valve replacement to treat severe calcified rheumatic native mitral stenosis: role of three-dimensional printing-a case report

How to Manage Mitral Stenosis Due to Mitral Annular Calcification

Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification

Combined transcatheter aortic valve and tricuspid valve‐in‐valve implantation in a patient with a mitral mechanical prosthesis

Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series

Transcatheter Mitral Valve Replacement Using Annular Reduction by Cinching With TEER in the Commissure (ARCTIC)

Direct Implantation of Transcatheter Valve in Mitral Annular Calcification: A Multi-Center Study

Preliminary Evaluation of Transesophageal Echocardiography in Patients with Serious Calcific Aortic Stenosis Undergoing Transcatheter Aortic Corevalve Implantation

Feasibility and safety of transseptal transcatheter mitral valve replacement for severe mitral regurgitation

One Stone Hits Two Birds: Transcatheter Mitral Valve Edge-to-edge Repair for Hypertrophic Obstructive Cardiomyopathy and Severe Mitral Regurgitation

[Value of Preoperative Assessment on Transcatheter Aortic Valve Implantation Procedure with High-Pitch Dual-Source Computed Tomography Angiography].

Simultaneous transcatheter aortic and tricuspid valve replacement via bilateral cervical approach

Transcatheter Mitral Valve Implantation For Degenerated Mitral Bioprostheses Or Failed Surgical Annuloplasty Rings: A Systematic Review And Meta-Analysis

Percutaneous balloon mitral valvuloplasty with shockwave lithotripsy for the treatment of calcific mitral valve stenosis

Transcatheter mitral valve implantation via transapical approach: an early experience

Transcatheter Mitral Valve-in-Valve Implantation Applying a Long Pre-Curved Sheath for Patients with Degenerated Bioprosthetic Mitral Valve

Thrombosis of a mechanical aortic valve: stuck between a clot and a hard place

Haemolytic anaemia after transcatheter aortic valve replacement

Implications of Mitral Annular Calcification on Outcomes Following Mitral Transcatheter Edge-to-Edge Repair